相关实验视频

Updated: Jun 14, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

咖啡酸乙醇通过抑制毒素和调节微生物群来保护Clostridioides difficile感染

Yan Guo¹, Yong Zhang², Guizhen Wang³

¹State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, College of Veterinary Medicine, Jilin University, Center for Pathogen Biology and Infectious Diseases, The First Hospital of Jilin University, Changchun, China.

|June 11, 2025

概括

咖啡酸乙烯 (CAPE) 抑制了Clostridioides difficile毒素,降低了感染的严重程度并改善了肠道微生物群. 在C. difficile感染 (CDI) 中,CAPE显示出作为一种新疗法的潜力.

科学领域:

微生物学微生物学
药理学药理学是指药理学的学科.
胃肠病学胃肠病学

背景情况:

困难菌感染 (CDI) 是医院获得的腹的主要原因之一,由肠道失调驱动.
超病毒性菌株增加CDI的发病率,死亡率和复发率,需要新的治疗方法.
毒素TcdA和TcdB是CDI发病的关键,使它们成为抗病毒性疗法的目标.

研究的目的:

确定抑制TCdB的天然化合物,TCdB是C. difficile感染中的关键毒素.
调查咖啡酸乙 (CAPE) 对CDI的治疗潜力.

主要方法:

在自然化合物库中进行高通量表型选,以识别TcdB抑制剂.
关于CAPE与TcdB相互作用的机制研究,包括结合和酶活性抑制.
在C. difficile感染的小鼠模型中评估CAPE疗效.

主要成果:

咖啡酸乙烯 (CAPE) 被确定为TcdB的直接抑制剂.
CAPE抑制了TcdB的葡萄糖转移酶活性和InsP6诱导的自身蛋白解.
在小鼠中,CAPE治疗减少了CDI症状,细菌负载和组织损伤.
在受感染的小鼠中,CAPE调节了肠道微生物群多样性和代谢物概况.

结论:

CAPE显示了治疗C. difficile感染的治疗潜力.
CAPE可以作为开发针对TcdB的抗病毒药物的主要化合物.

关键词:

克洛斯特里迪奥伊德斯困难菌这就是TcdB的意思.我们的肠道微生物群.传染病是一种传染性疾病.微生物学的微生物.这里是鼠标鼠标鼠标鼠标鼠标鼠标.

更多相关视频

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...